Suppr超能文献

关于重复剂量毒性研究剂量水平选择的建议。

Recommendations on dose level selection for repeat dose toxicity studies.

机构信息

National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK.

Corteva Agriscience Italia S.R.L., Rome, Italy.

出版信息

Arch Toxicol. 2022 Jul;96(7):1921-1934. doi: 10.1007/s00204-022-03293-3. Epub 2022 Apr 29.

Abstract

Prior to registering and marketing any new pharmaceutical, (agro)chemical or food ingredient product manufacturers must, by law, generate data to ensure human safety. Safety testing requirements vary depending on sector, but generally repeat-dose testing in animals form the basis for human health risk assessments. Dose level selection is an important consideration when designing such studies, to ensure that exposure levels that lead to relevant hazards are identified. Advice on dose level selection is provided in test guidelines and allied guidance documents, but it is not well harmonised, particularly for selection of the highest dose tested. This paper further builds on concepts developed in a technical report by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) which recommends pragmatic approaches to dose selection considering regulatory requirements, animal welfare and state of the art scientific approaches. Industry sectors have differing degrees of freedom to operate regarding dose level selection, depending on the purpose of the studies and the regulatory requirements/legislation, and this is reflected in the overall recommended approaches. An understanding of systemic exposure should be utilised where possible (e.g., through toxicokinetic approaches) and used together with apical endpoints from existing toxicity studies to guide more appropriate dose level selection. The highest dose should be limited to a reasonable level, causing minimal but evident toxicity to the test animals without significantly compromising their well-being. As the science of predictive human exposure further develops and matures, this will provide exciting and novel opportunities for more human-relevant approaches to dose level selection.

摘要

在注册和销售任何新的药物、(农)化学品或食品成分产品之前,制造商必须依法生成数据以确保人类安全。安全测试要求因部门而异,但一般来说,动物重复剂量测试是人类健康风险评估的基础。在设计此类研究时,剂量水平的选择是一个重要的考虑因素,以确保确定导致相关危害的暴露水平。测试指南和相关指导文件提供了关于剂量水平选择的建议,但这些建议并没有很好地协调,特别是对于选择测试的最高剂量。本文进一步借鉴了欧洲生态毒理学和化学品毒理学中心 (ECETOC) 的一份技术报告中提出的概念,该报告建议考虑监管要求、动物福利和最新科学方法,采取务实的方法来选择剂量。不同的行业部门在剂量水平选择方面有不同程度的自由度,具体取决于研究的目的和监管要求/法规,这反映在总体推荐方法中。在可能的情况下,应利用全身暴露的知识(例如,通过毒代动力学方法),并结合现有毒性研究中的顶点终点来指导更合适的剂量水平选择。最高剂量应限制在合理水平,对试验动物造成最小但明显的毒性,而不会显著影响其健康。随着预测人类暴露的科学进一步发展和成熟,这将为更具人类相关性的剂量水平选择方法提供令人兴奋和新颖的机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验